Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib and Mezigdomide in Relapsed or Refractory AML
NCT07355335Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2026
- Primary completion
- Jul 2027
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ziftomenib and mezigdomide in acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 2 years and Recommended Phase 2 Dose at 48 weeks. Started Sep 2026; status: recruiting.
02
Drugs
ziftomenibmezigdomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07355335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355335.